- Home
- ABL vs TECX Comparison
ABL vs TECX Comparison
Compare ABL & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- TECX
- Stock Information
- Founded
- ABL 2004
- TECX 2019
- Country
- ABL United States
- TECX United States
- Employees
- ABL N/A
- TECX N/A
- Industry
- ABL Investment Managers
- TECX
- Sector
- ABL Finance
- TECX
- Exchange
- ABL Nasdaq
- TECX Nasdaq
- Market Cap
- ABL 661.9M
- TECX 387.1M
- IPO Year
- ABL N/A
- TECX 2018
- Fundamental
- Price
- ABL $7.15
- TECX $25.39
- Analyst Decision
- ABL Strong Buy
- TECX Strong Buy
- Analyst Count
- ABL 3
- TECX 5
- Target Price
- ABL $12.83
- TECX $79.00
- AVG Volume (30 Days)
- ABL 661.4K
- TECX 183.6K
- Earning Date
- ABL 08-07-2025
- TECX 08-07-2025
- Dividend Yield
- ABL N/A
- TECX N/A
- EPS Growth
- ABL N/A
- TECX N/A
- EPS
- ABL N/A
- TECX N/A
- Revenue
- ABL $161,724,466.00
- TECX N/A
- Revenue This Year
- ABL $77.22
- TECX N/A
- Revenue Next Year
- ABL $29.93
- TECX N/A
- P/E Ratio
- ABL N/A
- TECX N/A
- Revenue Growth
- ABL 69.56
- TECX N/A
- 52 Week Low
- ABL $4.60
- TECX $13.70
- 52 Week High
- ABL $10.95
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- ABL 77.06
- TECX 59.34
- Support Level
- ABL $6.23
- TECX $25.57
- Resistance Level
- ABL $7.03
- TECX $27.33
- Average True Range (ATR)
- ABL 0.27
- TECX 1.43
- MACD
- ABL 0.08
- TECX 0.20
- Stochastic Oscillator
- ABL 99.29
- TECX 76.91
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.